GlassScriptPhysician profile
Kenneth A Beasley
NPI 1710960414
$2,466.62
in general payments reported to CMS, 2019-2025
34 companies · $550 in 2025
The $550 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.48 · 2020: $389 · 2021: $116 · 2022: $203 · 2023: $508 · 2024: $689 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,698 · Education: $48.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,698.04 |
| Education | $48.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $314.41 | 2020-2025 | Itind System |
| Dendreon Pharmaceuticals LLC | $231.28 | 2020-2025 | Provenge |
| Teleflex LLC | $183.99 | 2023-2024 | Urolift |
| Abbvie INC. | $180.10 | 2021-2025 | Botox |
| Novartis Pharmaceuticals Corporation | $153.71 | 2025 | |
| Urogen Pharma, INC. | $136.51 | 2022-2025 | Jelmyto |
| Accord Healthcare, INC. | $128.33 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $122.35 | 2024-2025 | Adstiladrin |
| Merck Sharp & Dohme LLC | $110.44 | 2023-2024 | Keytruda, Lynparza |
| Myriad Genetic Laboratories, INC. | $105.69 | 2024-2025 | Prolaris |
| Axonics, INC. | $85.26 | 2023-2024 | Bulkamid, Axonics |
| Tolmar Pharmaceuticals, INC. | $84.04 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $68.73 | 2024-2025 | Givlaari |
| Neotract INC. | $60.46 | 2020 | |
| Urovant Sciences INC | $45.92 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $38.54 | 2020 | |
| Sumitomo Pharma America, INC. | $37.93 | 2024 | Orgovyx |
| 180 Medical, INC. | $37.17 | 2024-2025 | Gentlecath, Gentlecath Glide |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Coloplast Corp | $29.07 | 2019-2024 | |
| Amgen INC. | $28.34 | 2022 | |
| Telix Pharmaceuticals | $25.96 | 2025 | Illuccix |
| Boston Scientific Corporation | $23.97 | 2021 | |
| Progenics Pharmaceuticals, INC. | $23.57 | 2023 | Pylarify |
| Agiliti Surgical, INC. | $22.51 | 2023 | Sonablate |
| Vertex Pharmaceuticals Incorporated | $20.83 | 2025 | |
| Antares Pharma, INC. | $20.71 | 2022 | |
| Medtronic, INC. | $19.84 | 2025 | Altaviva |
| Bayer Healthcare Pharmaceuticals INC. | $19.32 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.97 | 2022 | |
| Myovant Sciences INC. | $15.12 | 2022 | |
| Verity Pharmaceuticals INC. | $14.39 | 2023 | Trelstar |
| Pfizer INC. | $13.07 | 2022 | |
| Intuitive Surgical, INC. | $13.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Beasley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.